CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment
Authors:
- Davide ChiasseriniDCDavide Chiasserini
- Alessia BellottiABAlessia Bellotti
- Alfredo MegaroAMAlfredo Megaro
- Giuseppe TringaliGiuseppe Tringali
- Ilenia CorbelliICIlenia Corbelli
- Elena CrestaECElena Cresta
- Valeria TetiVTValeria Teti
- Daniela FruttiniDFDaniela Fruttini
- Paolo CalabresiPCPaolo Calabresi
- Pierluigi NavarraPNPierluigi Navarra
- Lucilla ParnettiLucilla Parnetti
- Paola SarchielliPSPaola Sarchielli
Open Access
- 17 June 2026
- journal article
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (6)
Abstract
Aim: Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) play a crucial role in migraine pathophysiology. In recent years, anti-CGRP(R) monoclonal antibodies (mAbs) have emerged as the first targeted and highly effective therapy for migraine. This study aimed to assess any changes in plasma CGRP levels following prophylactic treatment with anti-CGRP(R) mAbs and to compare CGRP dynamics between anti-receptor (erenumab) and anti-ligand (galcanezumab, fremanezumab) therapies. Secondary objectives were: (i) to evaluate changes in VIP and PACAP plasma levels following treatment with anti-CGRP(R) mAbs and (ii) to investigate whether baseline or post-treatment plasma levels of CGRP, VIP and PACAP were associated with clinical response to anti-CGRP(R) monoclonal antibody therapy. Methods: Between February 2022 and February 2023, we enrolled 56 migraine patients who initiated prophylaxis with either erenumab (26 patients), galcanezumab (16 patients) or fremanezumab (14 patients). Responders were defined as those achieving a ≥50% reduction in monthly migraine days after six months. Blood samples were collected at baseline and at each follow-up visit (baseline, T0; three months, T1; six months, T2; 12 months, T3). Plasma levels of CGRP, VIP and PACAP were measured using a validated radioimmunoassay and commercially available enzyme-linked immunosorbent assay kits. Results: Overall, 80.3% (45 out of 56) of patients responded to anti-CGRP(R) mAbs. No correlation was found between baseline CGRP, VIP and PACAP plasma levels and clinical response to anti-CGRP(R) mAbs therapy. Regarding CGRP trend, significant differences were found between patients treated with the anti-receptor monoclonal antibody (erenumab) and those receiving anti-ligand therapies. In patients treated with erenumab, CGRP levels did not show a significant change over the treatment period (T1–T3), whereas, in the galcanezumab group, CGRP levels significantly decreased as early as T1 ( p < 0.01). CGRP longitudinal assessment of the fremanezumab group were excluded due to assay interference with the drug. VIP and PACAP plasma levels remained stable over time for all treatments, with no significant differences between responders and non-responders. Conclusions: Galcanezumab reduced CGRP plasmatic levels already after three months, whereas erenumab did not affect significantly CGRP plasmatic levels. VIP and PACAP levels were not influenced by the therapy.Keywords
Funding Information
- research grants provided by the Headache Center, University of Perugia
- Ricerca Corrente 2025 - Italian Ministry of Health - to PC, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome.
This publication has 55 references indexed in Scilit:
- Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyJournal of Neurology, 2024
- Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort studyNeuroImage: Clinical, 2023
- Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World AnalysisNeurotherapeutics, 2023
- Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its ReceptorAnnals of Neurology, 2023
- Serum CGRP, VIP, and PACAP usefulness in migraine: a case–control study in chronic migraine patients in real clinical practiceMolecular Biology Reports, 2020
- Monoclonal antibodies as a preventive therapy for migraine: A meta-analysisClinical Neurology and Neurosurgery, 2020
- Pituitary adenylate cyclase activating polypeptide and migraineAnnals of Clinical and Translational Neurology, 2014
- Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A reviewThe Journal of Headache and Pain, 2009
- Unitary hypothesis for multiple triggers of the pain and strain of migraineJournal of Comparative Neurology, 2005
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990